Build Your Comparison

Side-by-side financial analysis
TRNS logo
TRNS
TMO logo
TMO
JPM logo
JPM
Try popular comparisons:

Stock Comparison

TRNS vs TMO vs JPM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TRNS
Transcat, Inc.

Industrial - Distribution

IndustrialsNASDAQ • US
Market Cap$852M
5Y Perf.+252.9%
TMO
Thermo Fisher Scientific Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$174.42B
5Y Perf.+29.5%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$896.00B
5Y Perf.+241.0%

TRNS vs TMO vs JPM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TRNS logoTRNS
TMO logoTMO
JPM logoJPM
IndustryIndustrial - DistributionMedical - Diagnostics & ResearchBanks - Diversified
Market Cap$852M$174.42B$896.00B
Revenue (TTM)$333M$45.20B$280.33B
Net Income (TTM)$7M$6.86B$57.05B
Gross Margin32.6%39.4%60.0%
Operating Margin4.1%17.8%25.9%
Forward P/E51.9x18.9x14.4x
Total Debt$129M$40.85B$942.38B
Cash & Equiv.$5M$9.86B$343.34B

TRNS vs TMO vs JPMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TRNS
TMO
JPM
StockJun 20Jun 26Return
Transcat, Inc. (TRNS)100352.9+252.9%
Thermo Fisher Scien… (TMO)100129.5+29.5%
JPMorgan Chase & Co. (JPM)100341.0+241.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: TRNS vs TMO vs JPM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: JPM leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Thermo Fisher Scientific Inc. is the stronger pick specifically for capital preservation and lower volatility and operational efficiency and capital deployment. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
🥇JPM emerged as the overall leader. Track its performance:
TRNS
Transcat, Inc.
The Growth Play

TRNS is the clearest fit if your priority is growth exposure and long-term compounding.

  • Rev growth 19.2%, EPS growth -63.7%, 3Y rev CAGR 12.9%
  • 7.7% 10Y total return vs JPM's 465.8%
  • 19.2% revenue growth vs JPM's 3.3%
Best for: growth exposure and long-term compounding
TMO
Thermo Fisher Scientific Inc.
The Defensive Pick

TMO is the clearest fit if your priority is sleep-well-at-night and defensive.

  • Lower volatility, beta 0.91, Low D/E 76.3%, current ratio 1.89x
  • Beta 0.91, yield 0.4%, current ratio 1.89x
  • Beta 0.91 vs TRNS's 1.35
Best for: sleep-well-at-night and defensive
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM carries the broadest edge in this set and is the clearest fit for income & stability and valuation efficiency.

  • Dividend streak 15 yrs, beta 0.94, yield 1.9%
  • PEG 0.81 vs TMO's 8.94
  • Lower P/E (14.4x vs 18.9x), PEG 0.81 vs 8.94
Best for: income & stability and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthTRNS logoTRNS19.2% revenue growth vs JPM's 3.3%
ValueJPM logoJPMLower P/E (14.4x vs 18.9x), PEG 0.81 vs 8.94
Quality / MarginsJPM logoJPM20.4% margin vs TRNS's 2.0%
Stability / SafetyTMO logoTMOBeta 0.91 vs TRNS's 1.35
DividendsJPM logoJPM1.9% yield, 15-year raise streak, vs TMO's 0.4%, (1 stock pays no dividend)
Momentum (1Y)JPM logoJPM+21.8% vs TMO's +13.4%
Efficiency (ROA)TMO logoTMO6.4% ROA vs JPM's 1.3%, ROIC 7.5% vs 4.5%

TRNS vs TMO vs JPM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
TRNSTranscat, Inc.
FY 2025
Service
65.4%$217M
Distribution Service
34.6%$115M
TMOThermo Fisher Scientific Inc.
FY 2025
Consumables
41.9%$18.7B
Service
41.7%$18.6B
Instruments
16.4%$7.3B
JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000

TRNS vs TMO vs JPM — Financial Metrics

Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLJPMLAGGINGTRNS

Income & Cash Flow (Last 12 Months)

JPM leads this category, winning 5 of 6 comparable metrics.

JPM is the larger business by revenue, generating $280.3B annually — 842.9x TRNS's $333M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to TRNS's 2.0%. On growth, TRNS holds the edge at +15.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricTRNS logoTRNSTranscat, Inc.TMO logoTMOThermo Fisher Sci…JPM logoJPMJPMorgan Chase & …
RevenueTrailing 12 months$333M$45.2B$280.3B
EBITDAEarnings before interest/tax$40M$10.5B$81.4B
Net IncomeAfter-tax profit$7M$6.9B$57.0B
Free Cash FlowCash after capex$20M$6.7B$100.9B
Gross MarginGross profit ÷ Revenue+32.6%+39.4%+60.0%
Operating MarginEBIT ÷ Revenue+4.1%+17.8%+25.9%
Net MarginNet income ÷ Revenue+2.0%+15.2%+20.4%
FCF MarginFCF ÷ Revenue+5.9%+14.9%+36.0%
Rev. Growth (YoY)Latest quarter vs prior year+15.8%+6.2%
EPS Growth (YoY)Latest quarter vs prior year-56.3%+11.3%+16.0%
JPM leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

JPM leads this category, winning 6 of 7 comparable metrics.

At 16.0x trailing earnings, JPM trades at a 90% valuation discount to TRNS's 160.1x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.90x vs TMO's 12.53x — a lower PEG means you pay less per unit of expected earnings growth.

MetricTRNS logoTRNSTranscat, Inc.TMO logoTMOThermo Fisher Sci…JPM logoJPMJPMorgan Chase & …
Market CapShares × price$852M$174.4B$896.0B
Enterprise ValueMkt cap + debt − cash$976M$205.4B$1.50T
Trailing P/EPrice ÷ TTM EPS160.11x26.46x16.00x
Forward P/EPrice ÷ next-FY EPS est.51.85x18.88x14.40x
PEG RatioP/E ÷ EPS growth rate12.53x0.90x
EV / EBITDAEnterprise value multiple24.76x18.86x18.36x
Price / SalesMarket cap ÷ Revenue2.57x3.91x3.20x
Price / BookPrice ÷ Book value/share2.83x3.31x2.47x
Price / FCFMarket cap ÷ FCF43.60x27.72x8.88x
JPM leads this category, winning 6 of 7 comparable metrics.

Profitability & Efficiency

TMO leads this category, winning 5 of 9 comparable metrics.

JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $2 for TRNS. TRNS carries lower financial leverage with a 0.43x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), TMO scores 6/9 vs JPM's 5/9, reflecting solid financial health.

MetricTRNS logoTRNSTranscat, Inc.TMO logoTMOThermo Fisher Sci…JPM logoJPMJPMorgan Chase & …
ROE (TTM)Return on equity+2.2%+13.2%+15.9%
ROA (TTM)Return on assets+1.4%+6.4%+1.3%
ROICReturn on invested capital+2.6%+7.5%+4.5%
ROCEReturn on capital employed+3.3%+9.1%+8.9%
Piotroski ScoreFundamental quality 0–9565
Debt / EquityFinancial leverage0.43x0.76x2.60x
Net DebtTotal debt minus cash$124M$31.0B$599.0B
Cash & Equiv.Liquid assets$5M$9.9B$343.3B
Total DebtShort + long-term debt$129M$40.9B$942.4B
Interest CoverageEBIT ÷ Interest expense2.81x5.89x0.74x
TMO leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

JPM leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $10,136 for TMO. Over the past 12 months, JPM leads with a +21.8% total return vs TMO's +13.4%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.6% vs TMO's -3.3% — a key indicator of consistent wealth creation.

MetricTRNS logoTRNSTranscat, Inc.TMO logoTMOThermo Fisher Sci…JPM logoJPMJPMorgan Chase & …
YTD ReturnYear-to-date+59.7%-20.7%-0.5%
1-Year ReturnPast 12 months+17.9%+13.4%+21.8%
3-Year ReturnCumulative with dividends-1.0%-9.5%+138.2%
5-Year ReturnCumulative with dividends+66.3%+1.4%+118.2%
10-Year ReturnCumulative with dividends+769.1%+219.0%+465.8%
CAGR (3Y)Annualised 3-year return-0.3%-3.3%+33.6%
JPM leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — TRNS and TMO each lead in 1 of 2 comparable metrics.

TMO is the less volatile stock with a 0.91 beta — it tends to amplify market swings less than TRNS's 1.35 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TRNS currently trades 96.3% from its 52-week high vs TMO's 72.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTRNS logoTRNSTranscat, Inc.TMO logoTMOThermo Fisher Sci…JPM logoJPMJPMorgan Chase & …
Beta (5Y)Sensitivity to S&P 5001.35x0.91x0.94x
52-Week HighHighest price in past year$94.76$643.99$337.25
52-Week LowLowest price in past year$50.23$385.46$262.71
% of 52W HighCurrent price vs 52-week peak+96.3%+72.9%+95.1%
RSI (14)Momentum oscillator 0–10062.750.859.1
Avg Volume (50D)Average daily shares traded155K2.0M7.0M
Evenly matched — TRNS and TMO each lead in 1 of 2 comparable metrics.

Analyst Outlook

JPM leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: TRNS as "Buy", TMO as "Buy", JPM as "Buy". Consensus price targets imply 35.4% upside for TRNS (target: $124) vs 5.9% for JPM (target: $340). For income investors, JPM offers the higher dividend yield at 1.86% vs TMO's 0.36%.

MetricTRNS logoTRNSTranscat, Inc.TMO logoTMOThermo Fisher Sci…JPM logoJPMJPMorgan Chase & …
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$123.60$599.70$339.75
# AnalystsCovering analysts104261
Dividend YieldAnnual dividend ÷ price+0.4%+1.9%
Dividend StreakConsecutive years of raises0815
Dividend / ShareAnnual DPS$1.69$5.95
Buyback YieldShare repurchases ÷ mkt cap+0.1%+1.7%+3.9%
JPM leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

JPM leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). TMO leads in 1 (Profitability & Efficiency). 1 tied.

Best OverallJPMorgan Chase & Co. (JPM)Leads 4 of 6 categories
Loading custom metrics...

TRNS vs TMO vs JPM: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is TRNS or TMO or JPM a better buy right now?

For growth investors, Transcat, Inc.

(TRNS) is the stronger pick with 19. 2% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Transcat, Inc. (TRNS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — TRNS or TMO or JPM?

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus Transcat, Inc. at 160. 1x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus Thermo Fisher Scientific Inc. 's 8. 94x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — TRNS or TMO or JPM?

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to +1. 4% for Thermo Fisher Scientific Inc. (TMO). Over 10 years, the gap is even starker: TRNS returned +769. 1% versus TMO's +219. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — TRNS or TMO or JPM?

By beta (market sensitivity over 5 years), Thermo Fisher Scientific Inc.

(TMO) is the lower-risk stock at 0. 91β versus Transcat, Inc. 's 1. 35β — meaning TRNS is approximately 49% more volatile than TMO relative to the S&P 500. On balance sheet safety, Transcat, Inc. (TRNS) carries a lower debt/equity ratio of 43% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — TRNS or TMO or JPM?

By revenue growth (latest reported year), Transcat, Inc.

(TRNS) is pulling ahead at 19. 2% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Thermo Fisher Scientific Inc. grew EPS 7. 3% year-over-year, compared to -63. 7% for Transcat, Inc.. Over a 3-year CAGR, TRNS leads at 12. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — TRNS or TMO or JPM?

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus 1. 6% for Transcat, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus 4. 0% for TRNS. At the gross margin level — before operating expenses — JPM leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is TRNS or TMO or JPM more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus Thermo Fisher Scientific Inc. 's 8. 94x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 4x forward P/E versus 51. 9x for Transcat, Inc. — 37. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TRNS: 35. 4% to $123. 60.

08

Which pays a better dividend — TRNS or TMO or JPM?

In this comparison, JPM (1.

9% yield), TMO (0. 4% yield) pay a dividend. TRNS does not pay a meaningful dividend and should not be held primarily for income.

09

Is TRNS or TMO or JPM better for a retirement portfolio?

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Both have compounded well over 10 years (JPM: +465. 8%, TRNS: +769. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between TRNS and TMO and JPM?

These companies operate in different sectors (TRNS (Industrials) and TMO (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: TRNS is a small-cap high-growth stock; TMO is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while TRNS, TMO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.